Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer

International Journal of Urology

Volumn 19, Issue 7, 2012, Pages 639-644

  Yang, Zhongyi ^a,b   Pan, Lingling ^a,b   Cheng, Jingyi ^a,b   Hu, Silong ^a,b   Xu, Junyan ^a,b   Ye, Dingwei ^a,b   Zhang, Yingjian ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Bladder cancer; Fluorine 18 fluorodeoxyglucose; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CANCER; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; WHOLE BODY PET;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, SMALL CELL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84862775091     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.02989.x     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol. 2000; 163: 1693-6.
3. Yaman O, Baltaci S, Arikan N, Yilmaz E, Gögüs O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br. J. Urol. 1996; 78: 197-200.
4. Baltaci S, Resorlu B, Yagci C, Turkolmez K, Gogus C, Beduk Y. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol. Int. 2008; 81: 399-402.
5. Podoloff DA, Ball DW, Ben-Josef E etal. NCCN task force: clinical utility of PET in a variety of tumor types. J. Natl. Compr. Canc. Netw. 2009; 7: S1-26.
6. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 1412-17.
7. Apolo AB, Riches J, Schöder H etal. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J. Clin. Oncol. 2010; 28: 3973-8.
8. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur. J. Nucl. Med. 1997; 24: 615-20.
9. Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J. Nucl. Med. 2007; 48: 764-70.
10. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010; 106: 658-3.
11. Kibel AS, Dehdashti F, Katz MD etal. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol. 2009; 27: 4314-20.
12. Liu IJ, Lai YH, Espiritu JI etal. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol. Int. 2006; 77: 69-75.
13. Swinnen G, Maes A, Pottel H etal. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 2010; 57: 641-7.
14. Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int. J. Clin. Oncol. 2008; 13: 42-7.
15. Heicappell R, Müller-Mattheis V, Reinhardt M etal. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur. Urol. 1999; 36: 582-7.
16. Weissleder R. Molecular imaging in cancer. Science 2006; 312: 1168-71.
17. Hoffman JM, Gambhir SS. Molecular imaging. the vision and opportunity for radiology in the future. Radiology 2007; 244: 39-47.
18. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu. Rev. Med. 2006; 57: 99-118.
19. Jager PL, de Korte MA, Lub-de Hooge MN etal. Molecular imaging: what can be used today. Cancer Imaging 2005; 5: S27-32.
20. Andrade RS, Heron DE, Degirmenci B etal. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 2006; 65: 1315-22.
21. Fukui MB, Blodgett TM, Snyderman CH etal. Combined PET-CT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005; 25: 913-30.
22. De Wever W, Meylaerts L, De Ceuninck L, Stroobants S, Verschakelen JA. Additional value of integrated PET-CT in the detection and characterization of pulmonary metastases: correlation with CT alone and PET alone. Eur. Radiol. 2007; 17: 467-73.
23. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am. J. Roentgenol. 2000; 174: 1005-8.
24. Moulin-Romsee G, Spaepen K, Stroobants S, Mortelmans L. Non-Hodgkin lymphoma: retrospective study on the cost-effectiveness of early treatment response assessment by FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1074-80.